SCHEMBL17989

SCHEMBL17989

COc1ncccc1C[C@H](NC(=O)CNC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACE P12821 2/20 0.47
PTPN1 P18031 1/20 0.42
CTSS P25774 5/20 0.41
CTSK P43235 4/20 0.41
SCN9A Q15858 5/20 0.40
CYP3A4 P08684 2/20 0.40
SCN10A Q9Y5Y9 1/20 0.40
KLK5 Q9Y337 1/20 0.40
SLC13A5 Q86YT5 1/20 0.40
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
PPARA Q07869 2/20 0.39
PPARG P37231 1/20 0.39
ITGB3 P05106 1/20 0.38
ITGA2B P08514 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17988 1.00 ACE (0.47) ACEPTPN1CTSSCTSKSCN9A
SCHEMBL18238 0.89 SCN9A (0.41) CTSSCTSKSCN9ACYP3A4SCN10A
SCHEMBL18239 0.89 SCN9A (0.41) CTSSCTSKSCN9ACYP3A4SCN10A
SCHEMBL30705546 0.81 TACR1 (0.48) ACECTSSCTSKSCN9ACYP3A4
SCHEMBL18154504 0.80 ACE (0.69) ACECTSSCTSKKLK5CTSL
SCHEMBL10688353 0.80 ACE (0.69) ACECTSSCTSKKLK5CTSL
SCHEMBL30487469 0.80 ACE (0.69) ACECTSSCTSKKLK5CTSL
SCHEMBL30705643 0.80 REN (0.46) ACECTSSCTSKSCN9ACYP3A4
SCHEMBL18495333 0.78 ACE (0.66) ACEPTPN1CTSSCTSKKLK5
SCHEMBL11862942 0.78 ACE (0.66) ACEPTPN1CTSSCTSKKLK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609081-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES Amgen Inc. (US) 2013-07-03 EP disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed